Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer now, its future pharma growth could be in jeopardy.
It's become well-recognized that pharma companies need to move beyond the "not invented here" mindset and tap into the scientific expertise of academic centers. And Takeda just took a big step in that direction.
In a development that’s getting the pharma some credit with the international charity Médecins Sans Frontières, GSK said Monday it’ll lower the price of its pneumococcal vaccine Synflorix in certain situations.
After months of work under the radar, GlaxoSmithKline committed to entering the Zika R&D field, announcing on Thursday that it’s pairing with the National Institutes of Health in a project based at its new vaccine research hub in Rockville, MD.
Lending its vaccines expertise to a leading Zika candidate, Sanofi has teamed up with the U.S. Army’s Walter Reed Army Institute of Research to guide an inactivated Zika vaccine candidate through clinical development.
Trouble is brewing out west for sea lions. A new study shows that California sea lions exposed to a toxin produced by a certain type of algae have permanent brain damage that spurs memory loss and behavioral changes, which could affect the animals' ability to survive in the wild and have negative implications for the seafood industry.